Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Blood test 4 EDTA tubes.
- Who it may be relevant to
- Registry conditions: Inflammatory Bowel Disease (IBD). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Inflammatory bowel diseases, Crohn's disease and haemorrhagic rectocolitis, are pathologies that progress in flare-ups, impacting on patients' quality of life and functional or even vital prognosis. These inflammatory diseases require the use of immunosuppressive and immunomodulatory treatments, the side-effects of which can be significant, and the limited number of which sometimes puts patients and practitioners in a therapeutic impasse from which surgery is the only way out. It is therefore important to be able to develop new therapeutic approaches, ideally better tolerated, that can control inflammation during relapses. Monocytes are one of the main players in the inflammatory reaction. In the laboratory, we have developed a strategy for the metabolic reprogramming of these cells based on the use of oxygen microbubbles to modulate the inflammatory response of monocytes.
Interventions
- Biological Blood test 4 EDTA tubes
Blood test 4 EDTA tubes for biological check-up
Primary outcome measures
- Comparaison of reduction of concentration of inflammatory cytokines and chemokines in cells treated by oxygen microbubbles vs cells not treated [Time frame: up to 2 years]
Secondary outcome measures (2)
- Comparaison of tissue factor expression at the membrane of monocytes treated by microbubbles vs monocytes not treated [Time frame: up to 2 years]
- Comparaison of glucose metabolism rate in monocytes treated bu microbubbles vs not treated cells [Time frame: up to 2 years]
Eligibility criteria
Inclusion criteria
- Men and women over 18
- Managed at the CHUGA for a severe IBD flare-up requiring hospitalisation or endoscopy for flare-up
- Patient not objecting to the REPRO-MICI study
Exclusion criteria
- Patients protected by law (pregnant or breast-feeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalised under duress).
- Patients with positive HIV, HBV or HCV serology.
- Patients with a positive ELISPOT with no history of treatment for latent tuberculosis.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
France · 1 center
- Grenoble Alpes University Hospital — La Tronche
Identifiers
NCT: NCT06944873 · 38RC24.0363